Check for updates

REVIEW

Advances in understanding hypopituitarism [version 1; peer review: 2 approved]

Mareike R. Stieg, Ulrich Renner, Günter K. Stalla, Anna Kopczak

Max Planck Institute of Psychiatry, Clinical Neuroendocrinology, Kraepelinstr. 2-10, D-80804 Munich, Germany

V1 First published: 22 Feb 2017, 6(F1000 Faculty Rev):178<https://doi.org/10.12688/f1000research.9436.1>

Latest published: 22 Feb 2017, 6(F1000 Faculty Rev):178

<https://doi.org/10.12688/f1000research.9436.1>

Abstract

The understanding of hypopituitarism has increased over the last three years. This review provides an overview of the most important recent findings. Most of the recent research in hypopituitarism has focused on genetics. New diagnostic techniques like next-generation sequencing have led to the description of different genetic mutations causative for congenital dysfunction of the pituitary gland while new molecular mechanisms underlying pituitary ontogenesis have also been described. Furthermore, hypopituitarism may occur because of an impairment of the distinctive vascularization of the pituitary gland, especially by disruption of the long vessel connection between the hypothalamus and the pituitary. Controversial findings have been published on post-traumatic hypopituitarism. Moreover, autoimmunity has been discussed in recent years as a possible reason for hypopituitarism. With the use of new drugs such as ipilimumab, hypopituitarism as a side effect of pharmaceuticals has come into focus. Besides new findings on the pathomechanism of hypopituitarism, there are new diagnostic tools in development, such as new growth hormone stimulants that are currently being tested in clinical trials. Moreover, cortisol measurement in scalp hair is a promising tool for monitoring cortisol levels over time.

Keywords

hypopituitarism , combined pituitary hormone deficiency , isolated growth hormone deficiency , post-traumatic hypopituitarism , vascularization , Sheehan`s syndrome

Open Peer Review

Approval Status

	1	2
version 1
22 Feb 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Ulla Feldt-Rasmussen**, National University Hospital, Copenhagen, Denmark
2. **Fahrettin Keleştimur**, Erciyes University Medical School, Kayseri, Turkey

Any comments on the article can be found at the end of the article.

Corresponding author: Anna Kopczak (anna_kopczak@psych.mpg.de)

Competing interests: The authors declare that they have no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Stieg MR *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Stieg MR, Renner U, Stalla GK and Kopczak A. **Advances in understanding hypopituitarism [version 1; peer review: 2 approved]** F1000Research 2017, 6(F1000 Faculty Rev):178 <https://doi.org/10.12688/f1000research.9436.1>

First published: 22 Feb 2017, 6(F1000 Faculty Rev):178 <https://doi.org/10.12688/f1000research.9436.1>

Introduction

Hypopituitarism is defined as a diminished function of the pituitary gland. First described in 1914 by Simmonds, it is also known as Simmonds' disease¹. There are two main reasons for the hypofunction of the pituitary gland: it can result from pituitary dysfunction *per se* or from hypothalamic damage. In both cases, the production of pituitary hormones is diminished. When a single pituitary hormone is affected, this is called isolated pituitary deficiency. When two or more pituitary hormones are affected, this is referred to as multiple pituitary hormone deficiency. Panhypopituitarism is a state of reduction of all pituitary hormones.

Hypopituitarism may result from different causes and can be congenital or acquired. The most common causes are listed in Table 1. Depending on the specific anatomic lesion, patients present with different endocrine abnormalities. These either can be detected during newborn screenings such as congenital hypothyroidism or may present later in life (for example, with growth retardation or absence of puberty). As hypopituitarism may be associated with malformations of the central nervous system, such as malformation of the optic nerve, patients may present with different grades of sensory impairments. Acquired hypopituitarism can occur in all age groups and needs careful consideration of treatment indication depending on the nature and degree of the affected hormone axis.

Table 1. Most common causes of hypopituitarism.

Etiology	Underlying cause/disease (examples)
Congenital	<ul style="list-style-type: none"> Idiopathic (without anatomical lesion or association with syndromic disease) With anatomic lesion in the sella region (for example, primary empty sella syndrome or Rathke's cyst) Associated with malformations of the central nervous system (for example, septo-optic-dysplasia, Kallmann syndrome, and pituitary stalk interruption syndrome)
Acquired	<ul style="list-style-type: none"> Pituitary tumor (mainly displacing macroadenoma) Craniopharyngeoma Transsphenoidal or transcranial surgery in the hypothalamo-pituitary region Cranial radiation Systemic cancer treatment Traumatic brain injury Sheehan's syndrome Apoplexy Subarachnoid hemorrhage Meningitis Hypophysitis Meningioma in the sella region Lymphoma Wegener's granulomatosis Hemochromatosis

Genetic causes of congenital hypopituitarism

Despite recent advances, genetic causes are still not identified in the majority of patients with congenital hypopituitarism. Affected patients can be subdivided into two groups: one with concomitant association with extra-pituitary abnormalities (syndromic diseases) and the other presenting with hypopituitarism alone. Congenital hypopituitarism may be isolated with a loss of function of a single pituitary axis or presenting with dysfunction of two or more pituitary axes. However, initial diagnosis of isolated growth hormone deficiency (GHD) may frequently develop into multiple pituitary hormone deficiencies as described in a long-term observational study with a mean follow-up of more than 15 years². Analysis of the KIMS database (Pfizer International Metabolic Database) has shown that hypopituitarism in adults seems to be a dynamic condition where new hormone deficiencies may occur even years after initial diagnosis of isolated pituitary hormone deficiency³.

The diagnosis of congenital causes for hypopituitarism can be challenging. Sequencing technologies may provide the underlying genetic cause. Sanger sequencing can be used if a single gene mutation is suspected because of the patient's phenotype. More often, a multi-panel test seems to be more appropriate if no obvious clinical phenotype or magnetic resonance imaging finding is present. More recently, developed techniques such as next-generation sequencing and whole exome sequencing allow for the analysis of several relevant genes in parallel or coding regions of all genes, respectively. It has to be kept in mind that only 10% of cases with hypopituitarism can be explained by genetic alterations known so far⁴. Epigenetic alterations, mosaicism, and oligonucleotide repeat expansions as well as alterations outside the coding regions cannot be detected by the above-mentioned sequencing techniques. However, owing to these improved diagnostic tools, there have been several causative genetic alterations identified in the last few decades, ranging from chromosomal abnormalities to single gene mutations^{4,5}. The most recent publications will be summarized here briefly.

In general, alterations in transcription factors implicated in pituitary organogenesis can be pituitary-specific, such as mutations in *POU1F1*, or can affect different tissues, as is the case in *OTX2* mutations where pituitary deficiency is usually associated with severe eye abnormalities. In a recently published case report, an *OTX2* mutation was identified in a neonate presenting with adrenocorticotrophic hormone deficiency, bilateral microphthalmia, and agenesis of the left internal carotid artery, expanding the spectrum of pathophysiology associated with *OTX2* mutations⁶.

In patients with hypogonadotropic hypogonadism (in combination with anosmia, known as Kallmann syndrome), plenty of genetic alterations affecting appropriate GnRH action have been described. Mutation in the genes *FEZF1*⁷, *SOX10*⁸, and *FGF17*, *IL17RD*, *SPRY4*, *DUSP6*, and *FLRT3*⁹ have been identified. Whether these single mutations alone are sufficient to cause disease remains unclear. For clinicians, a panel-testing approach in patients with hypogonadotropic hypogonadism/Kallmann syndrome is recommended⁵.

In patients with isolated GHD, genetic alterations hindering the release of functioning growth hormone have been identified. Mutations in the pituitary-specific transcription factor *POU1F1* usually lead to an altered somatotrophic, lactotropic, and thyrotrophic axis. Recently, a heterozygous missense mutation in *POU1F1* was identified as a causal trigger in a family with isolated GHD¹⁰. Moreover, a homozygous point mutation in the promotor region of the human growth hormone gene (*GHI*) was firstly described as causative for isolated GHD in siblings with normal pituitary imaging¹¹. These two studies demonstrate the possibility of familial heredity that is either autosomal dominant or autosomal recessive.

The Italian Study Group on Genetics of multiple pituitary hormone deficiencies recently published a systematic review investigating the mutation frequency in the most common altered genes, *PROPI*, *POU1F1*, *HESX1*, *LHX3*, and *LHX4*¹². The calculated prevalence of defects in these genes was quite low in the Italian study cohort (2.9% in sporadic and 12.5% in familial cases), and a worldwide prevalence of 12.4% has been estimated (from 11.2% in sporadic up to 63% in familial cases) identifying *PROPI* as the most frequent mutated gene. Genetic alterations of *PROPI* are usually associated with non-syndromic pituitary deficiencies. Nevertheless, dysfunction of this transcription factor can cause a variety of different phenotypes probably due to residual activity of altered protein synthesis¹³. Mutations in the non-pituitary-specific transcription factor *HESX1* are commonly associated with syndromic clinical features and have been linked to septo-optic dysplasia. However, dysfunction of *HESX1* may also present with a wide range of phenotypes¹⁴, making targeted genetic diagnostics in patients with multiple pituitary hormone deficiencies even more challenging.

It must also be kept in mind that the detection of a mutant gene does not mean dysfunction of the encoded product *per se*. High-performing genetic sequence analysis enables the detection of a variety of genetic mutations and variants of unknown significance, as demonstrated in an analysis of the transcription factor *GLI2*¹⁵. *GLI2* is a large polymorphic gene, and a relatively high frequency of *GLI2* mutations and variants were identified in patients with congenital GHD without further brain abnormalities. In mice, a link between *GLI2* mutations and prenatal ethanol exposure has been demonstrated, thereby implicating environmental factors in the etiology of *GLI2*-associated hypopituitarism¹⁵. Furthermore, variability in penetrance and not-yet-identified gene–gene interactions underline the need for functional studies in patients with hypopituitarism.

In patients with congenital holoprosencephaly, a midline defect with variable phenotypes, several genetic alterations in the sonic hedgehog signaling pathway have been identified. Pituitary stalk interruption syndrome and isolated pituitary hypoplasia have recently been proposed as mild phenotypic variants of holoprosencephaly, as several genetic mutations in holoprosencephaly-associated genes have been proven in both entities. Affected genes comprise *TGIF1* and *SHH*, both relevant in sonic hedgehog signaling¹⁶. In familial clustering of the disease, a homozygous mutation of *GPR161*, a gene coding for a G-protein-coupled receptor, was recently identified¹⁷. Moreover, detection of a novel mutation in the *CDON* gene

relevant in sonic hedgehog signaling¹⁸ reveals the broad spectrum of implicating variants in pituitary dysgenesis and dysfunction.

Hypopituitarism due to impaired hypophyseal blood supply

The anterior pituitary is one of the best-vascularized mammalian organs. Its high vessel density persists throughout the lifespan as the proper function of the pituitary is dependent on the rapid transportation of hypothalamic or peripheral factors from the bloodstream to the pituitary cells and the fast release of hypophyseal hormones into the blood^{19,20}. The intrapituitary vessel density is reduced in *PROPI*-deficient mice, a model of pituitary hormone deficiency. However, as in these mice the development of hormone-producing cells is also impaired, it is not clear whether disturbed hormone transportation due to the reduced vessel density contributes to hypopituitarism in these mice²¹.

In general, blood supply-dependent pituitary insufficiencies are rare²². Mechanical ruptures of the long portal blood vessels, which connect the pituitary with the hypothalamus, have been suggested to contribute to pituitary insufficiency in patients with traumatic brain injury (see the next section). In patients with congenital pituitary stalk interruption syndrome, it is still not known to which extent an impaired portal blood vessel system contributes to the hypopituitarism seen in these patients^{23,24}. Pituitary insufficiencies due to impaired hypophyseal blood supply are in most cases caused by compression of the long portal blood vessels or by pituitary apoplexy. Very often, these events are associated with or caused by pituitary tumors or local hemorrhages^{22,25,26}. Depending on the degree of blood flow impairment, a partial pituitary insufficiency can be observed in affected patients. This partial insufficiency can be reversible after normalizing the hypophyseal blood flow (for example, by removing the compressing structure)^{25,27}. Severe apoplexy leading to intrapituitary hypoxia and necrosis of hormone-producing cells is a life-threatening condition and needs rapid and proper treatment^{22,26}.

Reduced blood supply of the pituitary gland is attributed to Sheehan's syndrome, a common cause of hypopituitarism in post-partum women. The enlargement of the pituitary gland during pregnancy in combination with massive post-partum hemorrhage leads to a significant reduction of arterial blood flow and causes pituitary necrosis²⁸. The prevalence of Sheehan's syndrome might have decreased in recent years in some European countries and this is probably due to better obstetric care²⁸. In all other parts of the world, including the former Eastern European countries, the Middle East, the Mediterranean, and Africa, Sheehan's syndrome is still one of the most common causes of hypopituitarism. Signs and symptoms are often unspecific, and this may cause a delay in or impair correct diagnosis. A diagnostic delay of about 20 years was described and recently confirmed in Turkey^{29,30}. Recently, an increased expression of the coagulation factor V gene was reported in patients with Sheehan's syndrome³¹. However, gene polymorphisms in coagulation factors II and V and in tumor necrosis factor- α seemed not to be attributed to the pathogenesis of Sheehan's syndrome³². In general, the role of coagulation factors in Sheehan's syndrome has to be further elucidated.

Acquired hypopituitarism due to brain trauma

Acquired hypopituitarism can be observed in several neurological diseases. It was first described in a patient after traumatic brain injury leading to post-traumatic hypopituitarism³³. There are two distinct pathomechanisms causing post-traumatic hypopituitarism³⁴. The pituitary gland can be affected directly at the moment of the trauma (for example, by blast injuries, skull fractures with involvement of the sella turcica, or pituitary stalk disruptions). Not only do direct damages of the pituitary gland lead to hypopituitarism but also secondary effects of the trauma such as compression of the pituitary gland by brain swelling, impairment of the vascularization through swelling or vasospasms, and consecutive cell death of pituitary cells result in post-traumatic hypopituitarism.

Post-traumatic hypopituitarism may have causes other than just a single event. Repetitive concussions in contact sports such as football³⁵ or boxing³⁶ may also result in post-traumatic hypopituitarism.

As described above, the perfusion of the pituitary gland is crucial for the survival of pituitary cells. From an anatomical perspective, acidophil growth hormone-producing cells are located mainly at the periphery of the pituitary gland, thus making them sensitive to perfusion deficits and hypoxia. This fact contributes to the finding that somatotrophic insufficiency is the most frequent hormonal deficit after brain injury^{37–39}, especially in chronic patients^{40,41}.

Recently, this finding has been controversially discussed. In line with recent guidelines, GHD has to be defined by stimulation tests such as the insulin tolerance test or the growth hormone-releasing hormone (GHRH)–arginine test⁴². In a Danish National Study, only a low incidence of GHD of less than 1% after brain injury was reported when patients received a confirmatory stimulation test⁴³. Hence, the high prevalence and especially the relevance of post-traumatic GHD have been questioned⁴⁴.

This controversial discussion has extended to patients with subarachnoid hemorrhage (SAH). The first reports showed high prevalence rates of hypopituitarism after SAH of 47.5%^{38,45}, especially of GHD with a prevalence of 20 to 25% in chronic patients⁴⁶. Recent findings suggest that these high prevalence rates might be overestimated^{47,48}. The inclusion of different patient cohorts with distinct characteristics such as different severity grade of TBI/SAH and the use of different diagnostic tests might contribute to these controversial findings⁴⁹. This outlines that test stringency, especially for GHD, is very important in these patient cohorts. Additional diagnostic tools would be helpful. Recently, circulating microRNAs were identified in patients with post-traumatic hypopituitarism, suggesting that the microRNAs miR-126-3p and miR-3610 may act as potential biomarkers for hypopituitarism after TBI⁵⁰.

The diagnosis of hypopituitarism may be difficult in patients after brain injury, since signs and symptoms of pituitary dysfunction may overlap with chronic sequelae of TBI and SAH. However, it was shown that pituitary dysfunction had no effect on the commonly reported fatigue following SAH⁵¹. Moreover, endocrine disturbances such as hypogonadism and hypothyroidism may occur as physiological stress responses to critical illness in patients after

very severe brain injury, even long after the trauma⁵². Hence, pathological laboratory findings do not automatically implicate the presence of post-traumatic hypopituitarism⁵³.

But not only TBI and SAH may lead to hypopituitarism. Pituitary dysfunction also occurs after stroke with an estimated prevalence rate of about 19%. Thus, hypopituitarism seems to be less frequent in stroke patients than in patients after TBI or SAH⁵⁴. Despite the impact of stroke on morbidity and mortality, research on hypopituitarism after stroke has been very limited in recent years⁵⁵. Moreover, hypopituitarism may rarely occur after infectious diseases like encephalitis or meningitis^{56,57} and should be considered in these patients presenting with an unusual course.

In addition, cranial radiation is the most common cause of iatrogenic hypopituitarism⁵⁸. The radiation of brain or neck tumors may affect the pituitary gland, thus leading to hypopituitarism⁵⁹. In children with acute lymphoblastic leukemia, GHD seems to be the most common hormonal deficit after cranial radiation⁶⁰. In adults, an increasing prevalence of hypopituitarism from 12.5% after 2 years up to 90% 15 years after radiation has been reported⁶¹. As hypopituitarism due to cranial irradiation will increase as a consequence of more cancer patients receiving this treatment, establishing well-functioning collaboration between endocrinologists and oncologists is essential for adequate follow-up for these patients.

The role of autoantibodies in the pathophysiology of secondary hypopituitarism has been discussed in more detail in recent years. Damage of the pituitary integrity might expose pituitary antigens, leading to autoimmune-mediated damage of the pituitary gland in the presence of pituitary antibodies. However, the impact of pituitary antibodies on the pathophysiology of secondary hypopituitarism after brain injury remains unclear. There are several findings indicating that secondary hypopituitarism is associated with the presence of autoantibodies. These findings seem to be stable even years after the event⁶². However, it has to be kept in mind that there is no standardization or even proper validation of autoantibody assessment and such findings have not been confirmed by other research groups so far⁶³.

Auto-antibodies of the pituitary gland and the hypothalamus

Autoimmunity has recently been discussed as a further pathomechanism of hypopituitarism. Two different types of antibodies play a role in hypopituitarism: antipituitary antibodies and antihypothalamus antibodies.

Although antipituitary antibodies were first described in 1965 in a patient with Sheehan's syndrome⁶⁴, it is still not clear what their exact target is⁶⁵. Alpha-enolase, gamma-enolase, the pituitary gland-specific factors 1 and 2, and corticotroph-specific transcription factor (TPIT) have been discussed as possible targets of antipituitary antibodies⁶⁵. The measurement of antipituitary antibodies is complicated by different methodological problems, and the clinical use of antipituitary antibodies and antihypothalamus antibodies is very limited so far because of the lack of standardized and validated methods. In autoimmune hypophysitis, also known as lymphocytic hypophysitis, the measurement of antipituitary antibodies can be considered, but sensitivity and specificity are low⁶⁵.

Ricciuti *et al.* recently showed that antipituitary antibodies are more common in patients with pituitary diseases (24%) when compared with healthy controls (5%), but a discrimination of pituitary diseases has not been possible⁶⁶.

De Bellis *et al.*, in a longitudinal study, recently demonstrated that children with isolated GHD and high antipituitary antibody titers were not likely to show remission⁶⁷. Furthermore, antipituitary antibody-positive patients were at risk for delayed puberty due to hypogonadotropic hypogonadism. The presence of antipituitary antibodies may precede hypogonadism⁶⁸.

Less is known about antihypothalamus antibodies. These antibodies seem to target corticotropin-releasing hormone (CRH)-secreting cells in the hypothalamus⁶⁹. The presence of antihypothalamus antibodies was described in amateur boxers with hypopituitarism³⁶ as well as in patients with idiopathic hypopituitarism⁷⁰. In general, the literature on antihypothalamus antibodies is very scarce. A standardization and proper validation of methods are necessary for a better understanding of these results. This would also enable wider use of these autoantibody assessments.

Drug-induced hypopituitarism

The discussion of iatrogenic hypopituitarism has focused mainly on induction of autoimmune hypophysitis by immune checkpoint-inhibiting medication used in cancer treatment. A recently published review provides a good overview of the prevalence and pathophysiology of ipilimumab-induced autoimmune hypophysitis associated with pituitary dysfunction⁷¹. In brief, the incidence of hypophysitis is less than 10% with endocrine dysfunction occurring approximately 9 weeks after the initiation of therapy on average. Drug cessation and high-dose glucocorticoid administration have been proposed to manage these side effects. Continuation of the therapy may lead to hypopituitarism and can necessitate pituitary hormone substitution.

Recent developments in the diagnosis of hypopituitarism

In the case of suspected hypopituitarism, testing for the function of a single pituitary axis should be performed stepwise and according to the clinical presentation. Guidelines (for example, clinical practice guidelines of the Endocrine Society⁷²) provide advice for a reasonable screening and use of appropriate tests. However, there are some new developments in the diagnosis of isolated pituitary deficiencies, which will be highlighted here.

Analysis of human scalp hair has gained more attention in recent years. Originally used for consumption behavior in a forensic context, analysis of the content of steroids, mainly cortisol, has been proposed as a promising biomarker for individual cortisol exposure over a defined period of time⁷³. The sampling procedure is easy and non-invasive, and samples can be stored at room temperature for years. Determination of cortisol content in human scalp hair was recently used for retrospective determination of disease onset in a patient with primary adrenal insufficiency⁷⁴. Furthermore, measurement of hair cortisol content in patients with corticotroph insufficiency could be considered as a useful tool for therapy monitoring rather than as a diagnostic tool⁷³.

The diagnosis of GHD requires confirmation using a growth hormone stimulation test. The insulin hypoglycemia test represents the gold standard, but there are several contraindications and the test procedure is physically demanding for patients. Body mass index-related cutoff values are used in the GHRH-arginine test⁷⁵, and recent studies have emphasized new cutoff levels for the glucagon stimulation test, which seems to be an acceptable alternative to the insulin hypoglycemia test⁷⁶. Furthermore, new growth hormone stimulants for oral application are currently being validated in clinical trials^{77,78}.

Conclusion and future perspective

In patients with acquired pituitary insufficiency, understanding of the pathomechanisms has increased in recent years. The importance of a proper blood supply and the role of autoimmunity have been discussed. A more profound understanding of the underlying causes leading to secondary hypopituitarism may lead to recommendations for rational screening of hypopituitarism in more precisely defined risk populations and therefore may prevent under- or over-diagnosis.

Gene sequencing methods have markedly improved. New diagnostic tools led to the discovery of different genetic alterations in patients with congenital hypopituitarism. These mutations mainly affect genes important for pituitary ontogenesis. However, the diagnosis of congenital causes for hypopituitarism can be challenging and remains unsolved in the majority of patients. Depending on the phenotype and medical history of a single patient, an individual approach for stepwise genetic testing is essential. Increasing our understanding of molecular pathways relevant in pituitary function also includes expanding on current knowledge of pituitary cell differentiation and proliferation. Very recently, it was shown that pituitary cells seem to have the capability to regenerate, which provides a promising approach for therapeutic strategies for patients with permanent hypopituitarism⁷⁹. Nevertheless, activation of pituitary stem cells and cell transplantation in the treatment of pituitary insufficiency is still a long way off^{80,81}.

Author contributions

MRS performed the literature search on genetics, drug-induced hypopituitarism, and diagnostic findings and prepared the first draft of the manuscript. AK wrote the sections on acquired hypopituitarism and autoimmunity and revised the first draft. UR contributed to the section on vascularization. GKS added his expertise by carefully reading and revising the manuscript, especially the sections on Sheehan's syndrome and radiation-induced hypopituitarism. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Simmonds M: **Ueber Hypophysisschwund mit tödlichem Ausgang.** *Dtsch Med Wochenschr.* 1914; **40**(7): 322–323.
[Publisher Full Text](#)
2. Otto AP, Franca MM, Correa FA, *et al.*: **Frequent development of combined pituitary hormone deficiency in patients initially diagnosed as isolated growth hormone deficiency: a long term follow-up of patients from a single center.** *Pituitary.* 2015; **18**(4): 561–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
3. Klose M, Jonsson B, Abs R, *et al.*: **From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum - a KIMS analysis.** *Eur J Endocrinol.* 2009; **161**(Suppl 1): S75–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Castinetti F, Reynaud R, Quentien MH, *et al.*: **Combined pituitary hormone deficiency: current and future status.** *J Endocrinol Invest.* 2015; **38**(1): 1–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Larson A, Nokoff NJ, Meeks NJ: **Genetic causes of pituitary hormone deficiencies.** *Discov Med.* 2015; **19**(104): 175–83.
[PubMed Abstract](#)
6. Shimada A, Takagi M, Nagashima Y, *et al.*: **A Novel Mutation in OTX2 Causes Combined Pituitary Hormone Deficiency, Bilateral Microphthalmia, and Agenesis of the Left Internal Carotid Artery.** *Horm Res Paediatr.* 2016; **86**(1): 62–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
7. Kotan LD, Hutchins BI, Ozkan Y, *et al.*: **Mutations in FEZF1 cause Kallmann syndrome.** *Am J Hum Genet.* 2014; **95**(3): 326–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Pingault V, Bodereau V, Baral V, *et al.*: **Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness.** *Am J Hum Genet.* 2013; **92**(5): 707–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Miraoui H, Dwyer AA, Sykiotis GP, *et al.*: **Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.** *Am J Hum Genet.* 2013; **92**(5): 725–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
10. Sobrier ML, Tsai YC, Perez C, *et al.*: **Functional characterization of a human POU_{4F} mutation associated with isolated growth hormone deficiency: a novel etiology for IGHD.** *Hum Mol Genet.* 2016; **25**(3): 472–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
11. Madeira JL, Jorge AA, Martin RM, *et al.*: **A homozygous point mutation in the GH1 promoter (c.-223C>T) leads to reduced GH1 expression in siblings with isolated GH deficiency (IGHD).** *Eur J Endocrinol.* 2016; **175**(2): K7–K15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
12. De Rienzo F, Mellone S, Bellone S, *et al.*: **Frequency of genetic defects in combined pituitary hormone deficiency: a systematic review and analysis of a multicentre Italian cohort.** *Clin Endocrinol (Oxf).* 2015; **83**(6): 849–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
13. Ziemnicka K, Budny B, Drobnik K, *et al.*: **Two coexisting heterozygous frameshift mutations in PROP1 are responsible for a different phenotype of combined pituitary hormone deficiency.** *J Appl Genet.* 2016; **57**(3): 373–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Takagi M, Takahashi M, Ohtsu Y, *et al.*: **A novel mutation in HESX1 causes combined pituitary hormone deficiency without septo optic dysplasia phenotypes.** *Endocr J.* 2016; **63**(4): 405–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Arnhold JJ, Franca MM, Carvalho LR, *et al.*: **Role of GLI2 in hypopituitarism phenotype.** *J Mol Endocrinol.* 2015; **54**(3): R141–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
16. Tatsi C, Sertedaki A, Voutetakis A, *et al.*: **Pituitary stalk interruption syndrome and isolated pituitary hypoplasia may be caused by mutations in holoprosencephaly-related genes.** *J Clin Endocrinol Metab.* 2013; **98**(4): E779–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Karaca E, Buyukkaya R, Pehlivan D, *et al.*: **Whole-exome sequencing identifies homozygous GPR161 mutation in a family with pituitary stalk interruption syndrome.** *J Clin Endocrinol Metab.* 2015; **100**(1): E140–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
18. Bashamboo A, Bignon-Topalovic J, Rouba H, *et al.*: **A Nonsense Mutation in the Hedgehog Receptor CDON Associated With Pituitary Stalk Interruption Syndrome.** *J Clin Endocrinol Metab.* 2016; **101**(1): 12–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Rotondo F, Rotondo A, Jentoft M, *et al.*: **Microvessel density and VEGF expression in pituitaries of pregnant women.** *Hormones (Athens).* 2013; **12**(2): 292–7.
[PubMed Abstract](#)
20. Lloyd RV, Vidal S, Horvath E, *et al.*: **Angiogenesis in normal and neoplastic pituitary tissues.** *Microsc Res Tech.* 2003; **60**(2): 244–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Ward RD, Stone BM, Raetzman LT, *et al.*: **Cell proliferation and vascularization in mouse models of pituitary hormone deficiency.** *Mol Endocrinol.* 2006; **20**(6): 1378–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Giammattei L, Mantovani G, Carrabba G, *et al.*: **Pituitary apoplexy: considerations on a single center experience and review of the literature.** *J Endocrinol Invest.* 2016; **39**(7): 739–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Maghnie M, Genovese E, Villa A, *et al.*: **Dynamic MRI in the congenital agenesis of the neural pituitary stalk syndrome: the role of the vascular pituitary stalk in predicting residual anterior pituitary function.** *Clin Endocrinol (Oxf).* 1996; **45**(3): 281–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Wang W, Wang S, Jiang Y, *et al.*: **Relationship between pituitary stalk (PS) visibility and the severity of hormone deficiencies: PS interruption syndrome revisited.** *Clin Endocrinol (Oxf).* 2015; **83**(3): 369–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
25. Arafah BM, Prunty D, Ybarra J, *et al.*: **The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas.** *J Clin Endocrinol Metab.* 2000; **85**(5): 1789–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Glezer A, Bronstein MD: **Pituitary apoplexy: pathophysiology, diagnosis and management.** *Arch Endocrinol Metab.* 2015; **59**(3): 259–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Arafah BM, Kailani SH, Neel KE, *et al.*: **Immediate recovery of pituitary function after transphenoidal resection of pituitary macroadenomas.** *J Clin Endocrinol Metab.* 1994; **79**(2): 348–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Diri H, Karaca Z, Tanriverdi F, *et al.*: **Sheehan's syndrome: new insights into an old disease.** *Endocrine.* 2016; **51**(1): 22–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Diri H, Tanriverdi F, Karaca Z, *et al.*: **Extensive investigation of 114 patients with Sheehan's syndrome: a continuing disorder.** *Eur J Endocrinol.* 2014; **171**(3): 311–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. Gokalp D, Alpagat G, Tuzcu A, *et al.*: **Four decades without diagnosis: Sheehan's syndrome, a retrospective analysis.** *Gynecol Endocrinol.* 2016; **32**(11): 904–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
31. Bayram F, Diri H, Sener EF, *et al.*: **Genetic expressions of thrombophilic factors in patients with Sheehan's syndrome.** *Gynecol Endocrinol.* 2016; **32**(11): 908–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
32. Diri H, Sener EF, Bayram F, *et al.*: **Etiopathogenesis of Sheehan's Syndrome: Roles of Coagulation Factors and TNF-Alpha.** *Int J Endocrinol.* 2014; **2014**: 514891.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
33. Cyran E: **Hypophysenschädigung durch Schädelbasisfraktur.** *Dtsch Med Wochenschr.* 1918; **44**(45): 1261.
34. Tanriverdi F, Schneider HJ, Aimaretti G, *et al.*: **Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach.** *Endocr Rev.* 2015; **36**(3): 305–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Kelly DF, Chaloner C, Evans D, *et al.*: **Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study.** *J Neurotrauma.* 2014; **31**(13): 1161–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Tanriverdi F, Unluhizarci K, Karaca Z, *et al.*: **Hypopituitarism due to sports related head trauma and the effects of growth hormone replacement in retired amateur boxers.** *Pituitary.* 2010; **13**(2): 111–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Karaca Z, Tanriverdi F, Unluhizarci K, *et al.*: **GH and Pituitary Hormone Alterations After Traumatic Brain Injury.** *Prog Mol Biol Transl Sci.* 2016; **138**: 167–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, *et al.*: **Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review.** *JAMA.* 2007; **298**(12): 1429–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. Tanriverdi F, Kelestimur F: **Neuroendocrine Disturbances after Brain Damage: An Important and Often Undiagnosed Disorder.** *J Clin Med.* 2015; **4**(5): 847–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Kreber LA, Griesbach GS, Ashley MJ: **Detection of Growth Hormone Deficiency in Adults with Chronic Traumatic Brain Injury.** *J Neurotrauma.* 2016;

- 33(17): 1607–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. Krewer C, Schneider M, Schneider HJ, *et al.*: Neuroendocrine Disturbances One to Five or More Years after Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage: Data from the German Database on Hypopituitarism. *J Neurotrauma*. 2016; 33(16): 1544–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. **F** Gasco V, Prodam F, Pagano L, *et al.*: Hypopituitarism following brain injury: when does it occur and how best to test? *Pituitary*. 2012; 15(1): 20–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 43. **F** Klose M, Stochholm K, Janukonyté J, *et al.*: Prevalence of posttraumatic growth hormone deficiency is highly dependent on the diagnostic set-up: results from The Danish National Study on Posttraumatic Hypopituitarism. *J Clin Endocrinol Metab*. 2014; 99(1): 101–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 44. **F** Klose M, Feldt-Rasmussen U: Hypopituitarism in Traumatic Brain Injury-A Critical Note. *J Clin Med*. 2015; 4(7): 1480–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 45. Kreitschmann-Andermahr I, Hoff C, Saller B, *et al.*: Prevalence of pituitary deficiency in patients after aneurysmal subarachnoid hemorrhage. *J Clin Endocrinol Metab*. 2004; 89(10): 4986–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Karaca Z, Tanriverdi F, Dagli AT, *et al.*: Three years prospective investigation of pituitary functions following subarachnoid haemorrhage. *Pituitary*. 2013; 16(1): 76–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. **F** Hannon MJ, Behan LA, O'Brien MM, *et al.*: Chronic hypopituitarism is uncommon in survivors of aneurysmal subarachnoid haemorrhage. *Clin Endocrinol (Oxf)*. 2015; 82(1): 115–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 48. **F** Klose M, Brennum J, Poulsen L, *et al.*: Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage. *Clin Endocrinol (Oxf)*. 2010; 73(1): 95–101.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 49. Kokshoorn NE, Wassenaar MJ, Biermasz NR, *et al.*: Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. *Eur J Endocrinol*. 2010; 162(1): 11–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. **F** Taheri S, Tanriverdi F, Zararsiz G, *et al.*: Circulating MicroRNAs as Potential Biomarkers for Traumatic Brain Injury-Induced Hypopituitarism. *J Neurotrauma*. 2016; 33(20): 1818–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 51. **F** Khajeh L, Ribbers GM, Heijnenbroek-Kal MH, *et al.*: The effect of hypopituitarism on fatigue after subarachnoid hemorrhage. *Eur J Neurol*. 2016; 23(8): 1269–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 52. **F** Marina D, Klose M, Nordenbo A, *et al.*: Early endocrine alterations reflect prolonged stress and relate to 1-year functional outcome in patients with severe brain injury. *Eur J Endocrinol*. 2015; 172(6): 813–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 53. Kopczak A, Kilmann I, von Rosen F, *et al.*: Screening for hypopituitarism in 509 patients with traumatic brain injury or subarachnoid hemorrhage. *J Neurotrauma*. 2014; 31(1): 99–107.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Bondanelli M, Ambrosio MR, Zatelli MC, *et al.*: Prevalence of hypopituitarism in patients with cerebrovascular diseases. *J Endocrinol Invest*. 2008; 31(9 suppl): 16–20.
[PubMed Abstract](#)
 55. Karamouzis I, Pagano L, Prodam F, *et al.*: Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS). *Endocrine*. 2016; 52(3): 441–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Schaefer S, Boegershausen N, Meyer S, *et al.*: Hypothalamic-pituitary insufficiency following infectious diseases of the central nervous system. *Eur J Endocrinol*. 2008; 158(1): 3–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Vesely DL, Mastrandrea P, Samson C, *et al.*: Post-herpes encephalitic anterior pituitary insufficiency with hypothermia and hypotension. *Am J Med Sci*. 2000; 320(4): 273–7.
[PubMed Abstract](#)
 58. Sathiyapalan T, Dixit S: Radiotherapy-induced hypopituitarism: a review. *Expert Rev Anticancer Ther*. 2012; 12(5): 669–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. Ntali G, Karavitaki N: Efficacy and complications of pituitary irradiation. *Endocrinol Metab Clin North Am*. 2015; 44(1): 117–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Mirouliaei M, Shabani M, Bakhshi F, *et al.*: Radiation-induced hypopituitarism in children with acute lymphoblastic leukemia. *Indian J Med Paediatr Oncol*. 2013; 34(1): 8–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Appelman-Dijkstra NM, Malgo F, Neelis KJ, *et al.*: Pituitary dysfunction in adult patients after cranial irradiation for head and nasopharyngeal tumours. *Radiother Oncol*. 2014; 113(1): 102–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Tanriverdi F, de Bellis A, Ulutabanca H, *et al.*: A five year prospective investigation of anterior pituitary function after traumatic brain injury: is hypopituitarism long-term after head trauma associated with autoimmunity? *J Neurotrauma*. 2013; 30(16): 1426–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. **F** Guaraldi F, Grotoli S, Arvat E, *et al.*: Hypothalamic-Pituitary Autoimmunity and Traumatic Brain Injury. *J Clin Med*. 2015; 4(5): 1025–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 64. Engelberth O, Jezková Z: Letter to the editor: Autoantibodies in Sheehan's syndrome. *Lancet*. 1965; 285(7394): 1075.
[Publisher Full Text](#)
 65. Falorni A, Minarelli V, Bartoloni E, *et al.*: Diagnosis and classification of autoimmune hypophysitis. *Autoimmun Rev*. 2014; 13(4–5): 412–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Ricciuti A, de Remigis A, Landek-Salgado MA, *et al.*: Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. *J Clin Endocrinol Metab*. 2014; 99(5): 1758–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. **F** De Bellis A, Bellastella G, Maiorino MI, *et al.*: Longitudinal behavior of autoimmune GH deficiency: from childhood to transition age. *Eur J Endocrinol*. 2016; 174(3): 381–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 68. De Bellis A, Dello Iacovo A, Bellastella G, *et al.*: Characterization of pituitary cells targeted by antipituitary antibodies in patients with isolated autoimmune diseases without pituitary insufficiency may help to foresee the kind of future hypopituitarism. *Pituitary*. 2014; 17(5): 457–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. **F** De Bellis A, Sinisi AA, Pane E, *et al.*: Involvement of hypothalamus autoimmunity in patients with autoimmune hypopituitarism: role of antibodies to hypothalamic cells. *J Clin Endocrinol Metab*. 2012; 97(10): 3684–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 70. De Bellis A, Pane E, Bellastella G, *et al.*: Detection of antipituitary and antihypothalamus antibodies to investigate the role of pituitary or hypothalamic autoimmunity in patients with selective idiopathic hypopituitarism. *Clin Endocrinol (Oxf)*. 2011; 75(3): 361–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Joshi MN, Whitelaw BC, Palomar MT, *et al.*: Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. *Clin Endocrinol (Oxf)*. 2016; 85(3): 331–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. **F** Fleseriu M, Hashim IA, Karavitaki N, *et al.*: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2016; 101(11): 3888–921.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 73. **F** Wester VL, van Rossum EF: Clinical applications of cortisol measurements in hair. *Eur J Endocrinol*. 2015; 173(4): M1–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 74. **F** Ibrahim C, van Uum S: Hair analysis of cortisol levels in adrenal insufficiency. *CMAJ*. 2014; 186(16): 1244.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 75. Corneli G, Di Somma C, Baldelli R, *et al.*: The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. *Eur J Endocrinol*. 2005; 153(2): 257–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. **F** Yuen KC, Tritos NA, Samson SL, *et al.*: American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Update on Growth Hormone Stimulation Testing and Proposed Revised Cut-point for the Glucagon Stimulation Test in the Diagnosis of Adult Growth Hormone Deficiency. *Endocr Pract*. 2016; 22(10): 1235–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 77. Agrawal V, Garcia JM: The macimorelin-stimulated growth hormone test for adult growth hormone deficiency diagnosis. *Expert Rev Mol Diagn*. 2014; 14(6): 647–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Garcia JM, Swerdloff R, Wang C, *et al.*: Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. *J Clin Endocrinol Metab*. 2013; 98(6): 2422–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. **F** Willems C, Fu Q, Roose H, *et al.*: Regeneration in the Pituitary After Cell-Ablation Injury: Time-Related Aspects and Molecular Analysis. *Endocrinology*. 2016; 157(2): 705–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 80. Ellsworth BS: Pituitary Regeneration: It'll Knock Your SOX Off! *Endocrinology*. 2016; 157(2): 452–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. **F** Ozone C, Suga H, Eiraku M, *et al.*: Functional anterior pituitary generated in self-organizing culture of human embryonic stem cells. *Nat Commun*. 2016; 7: 10351.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Fahrettin Keleştimur**

Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey

Competing Interests: No competing interests were disclosed.

2. **Ulla Feldt-Rasmussen**

Department of Medical Endocrinology PE 2132, National University Hospital, Copenhagen, DK-2100, Denmark

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research